

HR 7646

Emerging Signals Modernization Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: May 3, 2022

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (May 3, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7646>

Sponsor

Name: Rep. Guthrie, Brett [R-KY-2]

Party: Republican • **State:** KY • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Moulton, Seth [D-MA-6]	D · MA		May 3, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	May 3, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 4349	Related bill	Jun 6, 2022: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of May 3, 2022)

Emerging Signals Modernization Act of 2022

This bill establishes certain requirements relating to the Food and Drug Administration's (FDA's) public notices on the potential new risks of approved medical devices (i.e., emerging signals), including with respect to the standards of evidence needed for such notices. The FDA must update its current guidance on emerging signals to align with the bill's requirements.

Actions Timeline

- **May 3, 2022:** Introduced in House
- **May 3, 2022:** Referred to the House Committee on Energy and Commerce.